Geranylgeranyl diphosphate synthase: an emerging therapeutic target

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Human Disease Pathogenesis

Background:

• Post-translational modification by geranylgeranylation influences numerous cellular processes relevant to human diseases.
• Recent advancements in cellular and animal models have significantly expanded the understanding of protein geranylgeranylation's biological roles.
• Medicinal chemistry has progressed in developing geranylgeranylation inhibitors, targeting enzymes like geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS).

Purpose of the Study:

• To review the advances and challenges in validating GGDPS as a novel therapeutic target.
• To assess the advantages of targeting GGDPS compared to other enzymes in the geranylgeranylation pathway.
• To provide a rationale for the further development of geranylgeranylation inhibition as a therapeutic strategy.

Main Methods:

• Literature review of recent studies on protein geranylgeranylation.
• Analysis of medicinal chemistry approaches targeting geranylgeranylation enzymes.
• Comparative assessment of GGDPS as a therapeutic target versus other geranylgeranylation enzymes.

Main Results:

• Significant progress has been made in understanding the biological roles of geranylgeranylated proteins.
• Geranylgeranylation inhibitors targeting GGDPS and other enzymes show therapeutic potential.
• Further in vivo studies are needed to confirm the efficacy of geranylgeranylation inhibition in various disease models.

Conclusions:

• GGDPS represents a promising therapeutic target for diseases involving aberrant geranylgeranylation.
• Targeting GGDPS offers potential advantages over inhibiting other enzymes in the pathway.
• Translational studies are crucial to validate geranylgeranylation inhibition for clinical applications.